Tome Biosciences, a gene-editing startup that received $213 million in funding, is reportedly struggling just nine months after launching. Sources claim that the company is winding down operations and seeking a buyer by November 1, although there are still options to keep the biotech running. The company attributes its challenges to a shift in investor sentiment within the gene-editing space. Tome’s spokesperson stated that they are operating at reduced capacity, maintaining core expertise, and exploring strategic options through confidential conversations with multiple parties.
Source link
Tome Biosciences, once a high-flying gene-editing startup, is floundering
